Potentiating the Cross-Reactive IFN-gamma T Cell and Polyfunctional T Cell Responses by Heterologous GX-19N DNA Booster in Mice Primed with Either a COVID-19 mRNA Vaccine or Inactivated Vaccine
SCIE
SCOPUS
- Title
- Potentiating the Cross-Reactive IFN-gamma T Cell and Polyfunctional T Cell Responses by Heterologous GX-19N DNA Booster in Mice Primed with Either a COVID-19 mRNA Vaccine or Inactivated Vaccine
- Authors
- Seo, Yong Bok; Ko, Ara; Shin, Duckhyang; Kim, Junyoung; Suh, You Suk; Na, Juyoung; Ryu, Ji In; Lee, Suyeon; Oh, Min Ji; Sung, Young Chul
- Date Issued
- 2023-06
- Publisher
- Multidisciplinary Digital Publishing Institute (MDPI)
- Abstract
- Waning vaccine-induced immunity, coupled with the emergence of SARS-CoV-2 variants, has inspired the widespread implementation of COVID-19 booster vaccinations. Here, we evaluated the potential of the GX-19N DNA vaccine as a heterologous booster to enhance the protective immune response to SARS-CoV-2 in mice primed with either an inactivated virus particle (VP) or an mRNA vaccine. We found that in the VP-primed condition, GX-19N enhanced the response of both vaccine-specific antibodies and cross-reactive T Cells to the SARS-CoV-2 variant of concern (VOC), compared to the homologous VP vaccine prime-boost. Under the mRNA-primed condition, GX-19N induced higher vaccine-induced T Cell responses but lower antibody responses than the homologous mRNA vaccine prime-boost. Furthermore, the heterologous GX-19N boost induced higher S-specific polyfunctional CD4(+) and CD8(+) T cell responses than the homologous VP or mRNA prime-boost vaccinations. Our results provide new insights into booster vaccination strategies for the management of novel COVID-19 variants.
- URI
- https://oasis.postech.ac.kr/handle/2014.oak/123698
- DOI
- 10.3390/ijms24119753
- ISSN
- 1661-6596
- Article Type
- Article
- Citation
- International Journal of Molecular Sciences, vol. 24, no. 11, 2023-06
- Files in This Item:
- There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.